Press Releases
Teva Pharmaceutical Inc suspends marketing for Zecuity in US
Teva Pharmaceutical Industries, Ltd. announced that it will voluntarily suspend sales, marketing and distribution of ZECUITY® (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients...
Press Releases
FDA Accepted Charleston Laboratories, Inc. and Daiichi Sankyo’s New Drug Application (NDA) for CL-108
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain while preventing or reducing the associated opioid-induced nausea...
Press Releases
Ziarco Pharma Ltd reports positive Phase 2a study results with ZPL-389
Ziarco Pharma Ltd a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, today announces positive, full results from its first Phase 2a proof of concept study with ZPL-389 in adults. ...
Press Releases
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
ViiV Healthcare announced that the US FDA has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets, reducing the weight limit from at least 40kg to at least 30kg, in ages 6 to less...
Press Releases
AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio
Agreement expands commercial reach for anaesthetics and supports the Company’s sharp focus on innovative new medicines in its three main therapy areas. AstraZeneca announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI),...
Press Releases
PCI Pharma Services’ Hay-on-Wye Site Launches New 3D Camera Technology from Scanware
PCI Pharma Services is installing specialist, innovative three-dimensional (3D) and high resolution color camera technology for product inspection and fill control on three of its blister packaging lines at its site in Hay-on-Wye, Wales. The state-of-the-art...
Press Releases
Janssen Phase 3 Data Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improved Signs
Janssen Research & Development, LLC announced results from a pivotal Phase 3 study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA)....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.